- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 30, 2024Navigating Generational Dynamics
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
May 6, 2024Litigating with the Legends
-
First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin
-
March 2024e-Commerce: Pitfalls and Protections
-
March 25, 2024Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
In re Bendamustine Consolidated Cases
Specification providing a list of alternative compounds may form the basis for the disclosure-dedication rule to preclude a claim of infringement under the doctrine of equivalents.
Summer 2015
Case Name: In re Bendamustine Consolidated Cases, Civ. No. 13-2046-GMS, 2015 U.S. Dist. LEXIS 55963 (D. Del. Apr. 29, 2015) (Sleet, J.)
Drug Product and Patent(s)-in-Suit: Treanda® (bendamustine HCl); U.S. Patents Nos. 8,436,190 ("the ’190 patent"), and 8,609,863 ("the '863 patent")
Nature of the Case and Issue(s) Presented: Cephalon filed a lawsuit against various defendants alleging patent infringement of at least one or more claims of the patents-in-suit. Defendants moved for a judgment on the pleadings with respect to Cephalon’s claims. The ’190 and ’863 patents claim compositions/preparations that include tertiary-butyl alcohol (“TBA”). Defendants’ ANDA products do not contain TBA.
Cephalon’s theory of infringement was premised on the doctrine of equivalents, rather than literal infringement. The only issue was whether Cephalon’s doctrine-of-equivalents argument was barred by the “disclosure-dedication rule.” The court found that it was.
Why Defendant Prevailed: The common specification for the patents-in-suit included a list of possible organic solvents, which included, “tertiary butanol, n-propanol, n-butanol, isopropanol, ethanol, methanol, acetone, ethyl acetate, dimethyl carbonate, acetonitrile, dichloromethane, methyl ethyl ketone, methyl isobutyl ketone, 1-pentanol, methyl acetate, carbon tetrachloride, dimethyl sulfoxide, hexafluoroacetone, chlorobutanol, dimethyl sulfone, acetic acid, and cyclohexane.” The specification identified TBA as the “more preferred organic solvent” of the list. But the ’190 and ’863 patents only claimed compositions or preparations containing TBA. Thus, defendants’ argument was premised on the application of the disclosure-dedicated doctrine because Cephalon provided a list of alternatives to TBA and not a broad genus in the specification and obtained only claims covering TBA.
In response, Cephalon argued that judgment on the pleadings was not proper because the Defendants sought to rely on documents outside of the pleadings. As such, the motion was a premature summary judgment motion that should be denied because factual issues existed. Cephalon also argued that simply listing alternatives was not a dedication to the public. Indeed, Cephalon had obtained another patent that included claims for such alternatives.
The court rejected Cephalon’s first argument. The patents-in-suit and the ANDA applications were properly considered by the court because those documents formed the basis of the allegations in the complaint, and thus could be considered for a motion for judgment on the pleadings without turning it into a summary judgment motion. And the court dismissed Cephalon’s second argument. The list of alternative solvents in the specification of the patents-in-suit made clear that the other compounds were alternatives to TBA. It did not include a description of a broad genus that included TBA and the other compounds. And the fact that Cephalon obtained a different patent that included the alternatives did not foreclose the application of the disclosure-dedication rule to the patents-in-suit.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.